Weekly Highlights (1 Nov – 8 Nov 2025)
1. Pine Labs Trims IPO Size
Pine Labs has cut the size of its upcoming IPO: existing shareholders will sell 44% fewer shares, and the fresh issue is reduced by 20%. The IPO is scheduled for 7–11 November 2025. This move signals caution amid a busy primary-market environment.
2. SBI Funds Management Ltd Stake Sale via IPO
The State Bank of India plans to divest a 6.3% stake in its asset-management arm via an IPO. Details on issue size and pricing are yet to be disclosed. The move is part of the bank’s strategy to unlock value and expand public participation.
3. NephroPlus Receives SEBI Approval for IPO
Hyderabad-based dialysis services provider NephroPlus has secured regulatory approval for an IPO comprising a fresh issue of ₹353.4 crore plus an offer for sale of 1.27 crore shares by existing shareholders. Funds will support new centres and debt repayment.
4. IPO Market Faces Valuation Reality
Major unlisted companies are finding that IPO pricing no longer mirrors their grey-market valuations. Large upcoming issues are being priced more conservatively, reflecting a shift from hype to fundamentals in pre-IPO valuations.
Key Takeaways for Investors
Even marquee IPOs are being scaled back, indicating that market sentiment may be slightly more cautious than before.
Firms filing or updating DRHPs (like Shadowfax) show that many companies are still keen to list — so pre-IPO and unlisted opportunities continue to remain relevant.
Big institutional moves (like by SBI) suggest that both listed and unlisted segments of financial services are under active focus.
If you’re holding or looking at unlisted shares, keep an eye on IPO timelines and market‐worth of the company — the IPO may reset the valuation benchmark.
Want to Buy or Sell Unlisted Shares?
🌐 Visit: www.unlistify.com
📞 +91 9958599459 | ✉ info@unlistify.com
We connect investors, shareholders, brokers and dealers in the unlisted and pre-IPO space with transparency, market insight and reliable execution.
